Figure 1

A) LA1-55n, 24h

B) IMR-5, 24h

C) NMB, 24h

D) LA1-55n, 48h

E) IMR-5, 48h

F) NMB, 48h

Relative number of cells

BIX-01294 (µg/ml)

0 0.5 1 2.5 5 10
Figure 2

A

<table>
<thead>
<tr>
<th>Control</th>
<th>BIX-01294</th>
</tr>
</thead>
<tbody>
<tr>
<td>H3K9Me2</td>
<td></td>
</tr>
<tr>
<td>H3K27Me2</td>
<td></td>
</tr>
<tr>
<td>H3</td>
<td></td>
</tr>
<tr>
<td>Actin</td>
<td></td>
</tr>
</tbody>
</table>

B

Relative H3K9Me2 expression

C

Relative H3K27Me2 expression

D

EHMT2 expression (fold)

CTRL | BIX-01294
Figure 3

A

![Figure A: Cell Cycle Distribution](image)

B

![Figure B: Western Blot](image)

C

![Figure C: P21 Expression](image)
Figure 4

A

Number of cells per field

CTRL

BIX-01294

Mobility

Invasion

B

24 h

MYCN expression

CTRL

BIX-01294

C

48 h

MYCN expression

CTRL

BIX-01294

D

BIX-01294 (µg/ml)

0

1

2.5

5

MYCN

β-actin
Figure 5

A. Caspase 3 activity (fold) with STS (1 µM) and BIX-01294 (µg/ml).

B. Caspase 8 activity (fold) with STS (1 µM) and BIX-01294 (µg/ml).

C. Relative number of living cells with Doxubicin (ng/ml).

D. Relative number of trypan blue positive cells with Doxrucin (ng/ml).

E. Relative number of trypan blue positive cells with CTRL, Doxubicin, BIX-01294, and Dox+BI.
Figure 6

A  

24h

% of 5mC

CTRL  BIX-01294

B  

48h

% of 5mC

CTRL  BIX-01294